The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
LRRK2 Antisense Oligonucleotides Ameliorate α-Synuclein Inclusion Formation in a Parkinson’s Disease Mouse Model
Open accessAbstract
No treatments exist to slow or halt Parkinson's disease (PD) progression; however, inhibition of leucine-rich repeat kinase 2 (LRRK2) activity represents one of the most promising therapeutic strategies. Genetic ablation and pharmacological LRRK2 inhibition have demonstrated promise in blocking α-synuclein (α-syn) pathology. However, LRRK2 kinase inhibitors may reduce LRRK2 activity in several tissues and induce systemic phenotypes in the kidney and lung that are undesirable. Here, we test whether antisense oligonucleotides (ASOs) provide an alternative therapeutic strategy, as they can be restricted to the CNS and provide a stable, long-lasting reduction of protein throughout the brain. Administration of LRRK2 ASOs to the brain reduces LRRK2 protein levels and fibril-induced α-syn inclusions. Mice exposed to α-syn fibrils treated with LRRK2 ASOs show more tyrosine hydroxylase (TH)-positive neurons compared to control mice. Furthermore, intracerebral injection of LRRK2 ASOs avoids unwanted phenotypes associated with loss of LRRK2 expression in the periphery. This study further demonstrates that a reduction of endogenous levels of normal LRRK2 reduces the formation of α-syn inclusions. Importantly, this study points toward LRRK2 ASOs as a potential therapeutic strategy for preventing PD-associated pathology and phenotypes without causing potential adverse side effects in peripheral tissues associated with LRRK2 inhibition.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity
West, A. B., Moore, D. J., Biskup, S., Bugayenko, A., Smith, W. W., Ross, C. A., Dawson, V. L., & Dawson, T. M. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0507360102 · Cited by 1,228 · cited 1×
“LRRK2 protein contains multiple conserved domains and functions as both a guanosine triphosphatase (GTPase) and kinase.(5,6) All known pathogenic mutations in LRRK2 increase its kinase activity.”
Self-citationKordasiewicz, H. B., Stanek, L. M., Wancewicz, E. V., Mazur, C., McAlonis, M. M., Pytel, K. A., Artates, J. W., Weiss, A., Cheng, S. H., Shihabuddin, L. S., et al. (2012) · Neuron · doi:10.1016/j.neuron.2012.05.009 · Cited by 770
Self-citationVolpicelli-Daley, L. A., Luk, K. C., & Lee, V. M.-Y. (2014) · Nature Protocols · doi:10.1038/nprot.2014.143 · Cited by 731 · cited 1×
“Primary hippocampal cultures were prepared from E16–E18 C57BL/ 6J mouse brains and maintained as described.(32,55) Fibril transduction was performed at 7 DIV at 2 mg/mL, together with 0.”
MethodSelf-citationInterplay of LRRK2 with chaperone-mediated autophagy
Orenstein, S. J., Kuo, S.-H., Tasset, I., Arias, E., Koga, H., Fernandez-Carasa, I., Cortes, E., Honig, L. S., Dauer, W., Consiglio, A., et al. (2013) · Nature Neuroscience · doi:10.1038/nn.3350 · Cited by 588 · cited 1×
“Consistent with this hypothesis, LRRK2 has been implicated in degradative processes(51) and was reported to have an inhibitory effect on chaperone-mediated autophagy, a mechanism reported to degrade a-syn.(52) Likewise, removing endogenous LRRK2 could enhance the degradation of aggregated a-syn, thereby”
BackgroundRigo, F., Chun, S. J., Norris, D. A., Hung, G., Lee, S., Matson, J., Fey, R. A., Gaus, H., Hua, Y., Grundy, J. S., et al. (2014) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.113.212407 · Cited by 283 · cited 2×
“Bolus intracerebral ventricular (ICVB) injection of ASOs into the lateral ventricles is an efficient method of ASO delivery.(29) To determine the potency of LRRK2 ASOs in vivo, wildtype C57BL/6J mice were treated with ASOs via ICVB, and tissues were harvested 14 days later.”
MethodAbrogation of α-synuclein–mediated dopaminergic neurodegeneration in LRRK2-deficient rats
Daher, J. P. L., Volpicelli-Daley, L. A., Blackburn, J. P., Moehle, M. S., & West, A. B. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1403215111 · Cited by 223 · cited 1×
“Furthermore, genetic ablation of LRRK2 or treatment with a potent LRRK2 kinase inhibitor protected against DA cell loss caused by viral-mediated overexpression of a-syn.(10,48) Finally, in G2019S LRRK2-expressing primary neurons and rat DA neurons, a-syn aggregation was significantly increased following exposure to a-…”
BackgroundSelf-citationAbdelmotilib, H., Maltbie, T., Delic, V., Liu, Z., Hu, X., Fraser, K. B., Moehle, M. S., Stoyka, L., Anabtawi, N., Krendelchtchikova, V., et al. (2017) · Neurobiology of Disease · doi:10.1016/j.nbd.2017.05.014 · Cited by 172
Self-citation
Cited by
Protein transmission in neurodegenerative disease
Peng, C., Trojanowski, J. Q., & Lee, V. M.-Y. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-020-0333-7 · Cited by 625
LRRK2 in Parkinson disease: challenges of clinical trials
Tolosa, E., Vila, M., Klein, C., & Rascol, O. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-019-0301-2 · Cited by 438
Progress towards therapies for disease modification in Parkinson's disease
Vijiaratnam, N., Simuni, T., Bandmann, O., Morris, H. R., & Foltynie, T. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00061-2 · Cited by 419
Lang, A. E., & Espay, A. J. (2018) · Movement Disorders · doi:10.1002/mds.27360 · Cited by 370
α-Synuclein pathology in Parkinson’s disease and related α-synucleinopathies
Henderson, M. X., Trojanowski, J. Q., & Lee, V. M.-Y. (2019) · Neuroscience Letters · doi:10.1016/j.neulet.2019.134316 · Cited by 291
Suppression of mutant C9orf72 expression by a potent mixed backbone antisense oligonucleotide
Tran, H., Moazami, M. P., Yang, H., McKenna-Yasek, D., Douthwright, C. L., Pinto, C., Metterville, J., Shin, M., Sanil, N., Dooley, C., et al. (2022) · Nature Medicine · doi:10.1038/s41591-021-01557-6 · Cited by 174
Perspective on the current state of the LRRK2 field
Taymans, J.-M., Fell, M., Greenamyre, T., Hirst, W. D., Mamais, A., Padmanabhan, S., Peter, I., Rideout, H., & Thaler, A. (2023) · npj Parkinson's Disease · doi:10.1038/s41531-023-00544-7 · Cited by 153
Taylor, M., & Alessi, D. R. (2020) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2020.01.001 · Cited by 141
Jafar-nejad, P., Powers, B., Soriano, A., Zhao, H., Norris, D. A., Matson, J., DeBrosse-Serra, B., Watson, J., Narayanan, P., Chun, S. J., et al. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkaa1235 · Cited by 128
“For example, selective spinal motor neuron degeneration occurs in SMA (33), motor neuron loss in both cortex and spinal cord occurs in ALS (34), selective degeneration of substantia nigra pars compacta dopaminergic neurons occurs in Parkinson’s disease (35), degeneration of neurons in the frontal cortex and hippocampu…”
BackgroundInfluentialSelf-citationAntisense drugs make sense for neurological diseases
Bennett, C. F., Kordasiewicz, H. B., & Cleveland, D. W. (2021) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010919-023738 · Cited by 108
Self-citationAntisense oligonucleotides for neurodegeneration
Leavitt, B. R., & Tabrizi, S. J. (2020) · Science · doi:10.1126/science.aba4624 · Cited by 96
Wu, X., Yang, Z., Zou, J., Gao, H., Shao, Z., Li, C., & Lei, P. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02179-x · Cited by 88
A single-cell map of antisense oligonucleotide activity in the brain
Mortberg, M. A., Gentile, J. E., Nadaf, N. M., Vanderburg, C., Simmons, S., Dubinsky, D., Slamin, A., Maldonado, S., Petersen, C. L., Jones, N., et al. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkad371 · Cited by 54
Self-citationBortolozzi, A., Manashirov, S., Chen, A., & Artigas, F. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107873 · Cited by 37
Brzozowski, C. F., Hijaz, B. A., Singh, V., Gcwensa, N. Z., Kelly, K., Boyden, E. S., West, A. B., Sarkar, D., & Volpicelli-Daley, L. A. (2021) · Acta Neuropathologica Communications · doi:10.1186/s40478-021-01283-7 · Cited by 32
Self-citationProtein kinase inhibitors as therapeutics in neurodegenerative and psychiatric disorders
Tridente, G., Jana, A., Nath, A., & Ashraf, G. M. (2023) · Receptor Tyrosine Kinases in Neurodegenerative and Psychiatric Disorders · doi:10.1016/b978-0-443-18677-6.00015-4 · Cited by 8
Metadata
- Authors
- Zhao, H. T., John, N., Delic, V., Ikeda-Lee, K., Kim, A., Weihofen, A., Swayze, E. E., Kordasiewicz, H. B., West, A. B., & Volpicelli-Daley, L. A.
- Venue
- Molecular Therapy - Nucleic Acids
- Publisher
- Elsevier BV
- Published
- 2017-09
- Volume
- 8
- Pages
- 508-519
- ISSN
- 2162-2531 (ISSN-L)
- OpenAlex
- W2743091325
- Cited by
- 212
- References
- 7
- FWCI
- 11.39
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.